Company intelligence / Profile preview

Botanix SB

Perth, Western Australia, Australia

Ownership: Private
Development stage: Other

Overview

Botanix Pharmaceuticals is an ASX-listed clinical-stage biotech specializing in dermatology and antimicrobial therapies, with a primary focus on synthetic cannabinoids and anticholinergics. Its lead asset (sofpironium bromide, for hyperhidrosis) is under FDA review; its dermatology pipeline targets acne, rosacea, and atopic dermatitis, while its antimicrobial program aims to prevent bloodstream infections in hemodialysis patients. The company is advancing toward commercialization, with manufacturing preparations underway and a healthy balance sheet. Clinical trials for synthetic CBD-based therapies have shown promising efficacy and safety[4][6].

Therapeutic areas: Infectious DiseasesDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Kaken Pharmaceutical (commercialization in Japan for sofpironium bromide)

Beyond the preview

Go deeper on Botanix SB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Botanix SB.

Explore the full profile